Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Warning Letter Draft Pilot Covers QSR, 510(k) And Labeling Violations

This article was originally published in The Gray Sheet

Executive Summary

Written explanations by manufacturers to FDA citations for quality system inspections, premarket notification submissions (510(k)) and labeling violations could prevent the agency from issuing a warning letter under a draft pilot program outlined in the Aug. 27 Federal Register.

You may also be interested in...

CBER Warning Letter Pilot, Other Device Initiatives Recommended

FDA's Center for Biologics Evaluation and Research should adopt the Center for Device and Radiological Health's warning letter pilot program for non-blood related devices, Gen-Probe Senior Director of Regulatory Affairs Glen Freiberg told an Oct. 6 session of the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts